Improving Sleep and Cognition in Alzheimer's Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Alzheimer Disease
Interventions
DIETARY_SUPPLEMENT

Citicoline supplement

Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.

OTHER

Placebo

Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.

Trial Locations (2)

30322

Emory University School of Nursing, Atlanta

30329

Goizueta Alzheimer's Disease Research Center, Atlanta

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Emory Goizueta Alzheimer's Disease Research Center (ADRC)

UNKNOWN

lead

Emory University

OTHER